Fei Li

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Venues

Annals of hematology

BMC cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

International journal of general medicine

南昌大学第一附属医院

First Affiliated Hospital of Nanchang University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

南昌大学第一附属医院

China

副主任 :: 血液科

First Affiliated Hospital of Nanchang University Jun 19 2014

China

associate director :: Department of Hematology

Education History

First Affiliated Hospital of Nanchang University Jun 30 1997

China

PHD :: Department of Hematology

Chinese Academy of Medical Sciences and Peking Union Medical College Sep 01 2010 - Jul 01 2013

China

PHD :: hematology

Publications

Ran Zhao, Dexiang Ji, Yulan Zhou, Ling Qi, Fei Li
Porcine Anti-Lymphocyte Globulin, Cyclosporine A Plus Thrombopoietin Receptor Agonists Achieved Similar Efficacy and Survival Compared to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia. International journal of general medicine 17 (2024)
Jie Jin, Hong Cen, Ke-Shu Zhou, Xiaohong Xu, Fei Li, Tao Wu, Haiyan Yang, Zhen Wang, Zhi-Ming Li, Wenyang Huang, Hanying Bao, Zusheng Xu, Lugui Qiu
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kebing Lv, Fancong Kong, Min Yu, Yulan Zhou, Fei Li
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Annals of hematology 103 (3) (2023)
Kebing Lv, Fancong Kong, Min Yu, Yulan Zhou, Fei Li
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Annals of hematology 103 (3) (2023)
Kebing Lv, Fancong Kong, Min Yu, Yulan Zhou, Fei Li
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Annals of hematology 103 (3) (2023)
Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhi-Ming Li, Yuqin Song, Li Zhang, Xiaojian Zhu, Huijing Wu, Wei Zhang, Junmin Li, Ke-Shu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zhenjiang Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Kebing Lv, Fancong Kong, Min Yu, Yulan Zhou, Fei Li
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Annals of hematology (2023)
Kebing Lv, Fancong Kong, Min Yu, Yulan Zhou, Fei Li
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Annals of hematology 103 (3) (2023)
Kebing Lv, Fancong Kong, Min Yu, Yulan Zhou, Fei Li
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Annals of hematology 103 (3) (2023)
Yulan Zhou, Fancong Kong, Shixuan Wang, Min Yu, Yawen Xu, Jing Kang, Songtao Tu, Fei Li
Increased levels of serum interleukin-10 are associated with poor outcome in adult hemophagocytic lymphohistiocytosis patients. Orphanet journal of rare diseases 16 (1) (2021)
Zhanglin Zhang, Zhiwei Chen, Mei Jiang, Shuyuan Liu, Yang Guo, Lagen Wan, Fei Li
Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia. BMC cancer 19 (1) (2019)
Fei Li, Xiaojie Zhang, Yunyun Wang, Ailin Yang, Zhanglin Zhang, Weiping Tang, Nan Zhong, Huidong Shi
Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. BMC cancer 18 (1) (2018)

Fei Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Fei Li